Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | Dexamethasone + Rovalpituzumab Tesirine |
| Synonyms | |
| Therapy Description | |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| Dexamethasone | Adexone | Desametasone | ||
| Rovalpituzumab Tesirine | Rova-T|SC16LD6.5 | Rovalpituzumab Tesirine (Rova-T) is an antibody drug conjugate of pyrrolobenzodiazepine (PBD) cytotoxin D6.5 and human anti-delta-like 3 (DLL3) antibody, which targets and kills DLL-3 expressing tumor cells (PMID: 26311731). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT03334487 | Phase III | Dexamethasone + Rovalpituzumab Tesirine | Study Evaluating the Safety of Rovalpituzumab Tesirine for Third-Line and Later Treatment of Subjects With Relapsed or Refractory Small Cell Lung Cancer | Withdrawn | USA | SWE | GBR | DEU | CAN | BRA | AUS | 0 |
| NCT03033511 | Phase III | Dexamethasone + Rovalpituzumab Tesirine | A Study of Rovalpituzumab Tesirine as Maintenance Therapy Following First-Line Platinum-Based Chemotherapy in Participants With Extensive Stage Small Cell Lung Cancer (MERU) (MERU) | Terminated | USA | TUR | SWE | POL | NOR | NLD | LVA | LTU | ITA | ISR | IRL | HUN | HRV | GRC | GBR | FRA | FIN | EST | ESP | DNK | DEU | CZE | CHE | CAN | BRA | BGR | BEL | AUT | AUS | 12 |